Chemcon Speciality Chemicals Q2 FY25: Revenue ₹52.6 Cr, EBITDA margin 16.2%
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹53Cr
- −30% YoY
- +15.6% QoQ
- Net profit
- ₹6Cr
- +6.6% YoY
- +17.9% QoQ
- Margin
- 16.18%
- +5.1 pp YoY
- +0.5 pp QoQ
Top 10 Chemicals & Petrochemicals companies on management guidance
See the sector's top 10 — free with your mobile number.
Chemcon Speciality Chemicals Ltd Q2 FY25 key numbers
- Revenue
- Q2 FY25 Revenue from Operations: Rs 52.6 Crs, down from Rs 75.2 Crs in Q2 FY24 (approx. -30% YoY).
As stated in Chemcon Speciality Chemicals Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Chemcon Speciality Chemicals Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY25 Revenue from Operations: Rs 52.6 Crs, down from Rs 75.2 Crs in Q2 FY24 (approx. -30% YoY). Q2 FY25 Financials (Page 6 & 8):
From Chemcon Speciality Chemicals Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY25 Revenue from Operations: Rs 52.6 Crs, down from Rs 75.2 Crs in Q2 FY24 (approx. -30% YoY).
- Sales Volume (MT) Q2 FY25: 2,877 MT vs. 2,851 MT in Q2 FY24 (slight increase YoY).
- Revenue Business-wise Q2 FY25: Organic Chemicals 30%, Inorganic Chemicals 68%, Others 2%.
- Revenue Geographic-wise Q2 FY25: Domestic 43%, Export 57%.
- Explicit Outlook:
- Soft performance due to subdued demand in organic chemicals (HMDS, CMIC, Bromobenzene) and volatility in inorganic chemicals.
2 more points from Chemcon Speciality Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Chemcon Speciality Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity Expansion involves adding two new organic chemical manufacturing units:
- Proposed P-10 unit expected by Q4 FY25
- Proposed P-11 unit expected by Q1 FY26
- Existing installed capacities:
- Organic Chemicals (HMDS, CMIC, Bromobenzene): 10,800 MTPA
- Inorganic Chemicals (Bromides): 15,000 MTPA
- Capital Work in Progress increased from Rs. 13.6 Cr (Mar-23) to Rs. 42.4 Cr (Mar-24), and further to Rs. 48.3 Cr (Sept-24), indicating ongoing investment in expansion projects.
2 more points from Chemcon Speciality Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Chemcon Speciality Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Chemcon Speciality Chemicals Ltd said on order book & pipeline — free account, 30 seconds.
Chemcon Speciality Chemicals Ltd — Quarterly revenue & net profit
Chemcon Speciality Chemicals Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 53 | 75 | -30% | 46 | +15.6% |
| Operating profit (EBITDA) | 9 | 8 | +2.2% | 7 | +19.5% |
| Operating margin | 16.18% | 11.08% | +5.1 pp | 15.64% | +0.5 pp |
| Profit before tax | 9 | 8 | +6.1% | 7 | +15.9% |
| Net profit (PAT) | 6 | 6 | +6.6% | 5 | +17.9% |
| EPS (₹) | 1.73 | 1.62 | +6.8% | 1.47 | +17.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹65 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Chemcon Speciality Chemicals's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Himadri Special (Q2 FY25)
1,135.21 Cr, up 13.01% YoY (Page 45) . Key concall takeaways from Himadri Speciality Chemical Ltd's Q2 FY25 earnings call — and how it ranks against sector…
- Vidhi Specialty (Q2 FY25)
Year-on-Year (Y-o-Y) growth: 13.9% (Page 8) . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q2 FY25 earnings call — and how it ranks…
- Valiant Organics (Q2 FY25)
Consolidated: INR 1,602 Mn (down 21.1% YoY from INR 2,031 Mn in Q2-FY24) . Key concall takeaways from Valiant Organics Ltd's Q2 FY25 earnings call — and how it…
- Excel Industries (Q2 FY25)
Q2 FY25 standalone revenue from operations: ₹269 crore, up 1.51% QoQ from Q1 FY25 (₹265 crore). Key concall takeaways from Excel Industries Ltd's Q2 FY25…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Chemcon Speciality Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Chemcon Speciality Chemicals Ltd Q2 FY25 results?
Q2 FY25 Revenue from Operations: Rs 52.6 Crs, down from Rs 75.2 Crs in Q2 FY24 (approx. -30% YoY). Q2 FY25 Financials (Page 6 & 8):
What is Chemcon Speciality Chemicals Ltd share price analysis?
Chemcon Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 28.1 with a market cap of ₹793 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Chemcon Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
